cjc+ipa blend
updated
CJC+IPA is a two-peptide blend of CJC-1295, a GHRH analogue that may be the long-acting DAC form or a different no-DAC molecule, and ipamorelin, a ghrelin-receptor agonist. Clinics pair them to raise the body's own growth hormone for sleep, recovery and body composition. The evidence is the parts' own: the two pathways together raise growth hormone more than either alone, but no trial has tested the finished blend or tied it to sleep, fat loss or healing. Graded A for that receptor-pair logic and component pharmacology; neither ingredient is FDA approved.
GHRH analog + ghrelin-receptor agonist
- GHRH analog + ghrelin-receptor agonist
- CJC identity and component amounts must be specified
What does CJC + ipamorelin actually contain?
The blend contains two peptides, but ‘CJC’ may mean CJC-1295 with DAC or material sold as CJC no DAC. Only the identified DAC form has multi-day human exposure data.
Why does DAC matter?
The drug-affinity-complex modification changes how the CJC component persists. The human long-acting data belong to the identified DAC material. A short name, a total vial weight or a claim of purity does not resolve which construct is present.
source: FDA · CJC forms and human exposure, FDA · CJC forms and human exposure
Has this exact combination been tested?
The cited records contain no controlled clinical outcome study of the specified CJC-1295/ipamorelin finished blend. Component studies and discussions of combined use do not establish a finished-blend outcome.
source: Exact combination · no controlled outcome study, PubMed and public trial records.
Does a bigger GH pulse mean better results?
The pairing can raise growth hormone through GHRH- and ghrelin-receptor pathways. Studies have not linked the size of that pulse to fat loss, sleep, or injury healing.
| Question | What the evidence can support |
|---|---|
| Sleep | Validated sleep outcomes with a comparison group, not reports of feeling more rested. |
| Body composition | Measured fat and lean-tissue changes, with diet, training and other hormones accounted for. |
| Recovery | Function, symptoms and injury-specific outcomes, rather than a hormone measurement alone. |
source: FDA · CJC forms and human exposure
source: Eight-man crossover · acute GH release, Tiulpakov AN et al. Clinical Endocrinology, 1995. PMID 7586605.
What side effects and unknowns matter?
No study provides an adverse-event rate for the finished blend. FDA describes serious reactions with CJC-1295 and incomplete route-specific safety information for ipamorelin.
Did ipamorelin cause deaths?
FDA notes deaths and other serious events in an intravenous gastric-motility study. That is an observed safety concern, not proof that ipamorelin caused every event. It also cannot be converted into a risk percentage for repeated subcutaneous use.
source: FDA · ingredient safety concerns, FDA · ingredient safety concerns
How long does it last, and is there a studied cycle?
The cited evidence contained no combined exposure curve or outcome-based cycle for the specified blend. Each ingredient can have a different time course. Neither an average of two half-lives nor the long-acting CJC result supplies a validated schedule for a mixed vial.
Does compounding make it an FDA-approved treatment?
A compounded combination does not acquire FDA approval from its ingredients, its prescriber or its pharmacy. A supplier also needs to establish the exact CJC form, amount of each ingredient and the finished preparation’s quality. None of those checks is a substitute for a clinical trial.
source: FDA · ingredient safety concerns
What doses have human studies used?
These are doses that cited human studies or FDA labels used, in the people they studied; none is a recommendation or a protocol. No published human study on file reports a dose for this compound.
Studies and sources
FDA · CJC forms and human exposure
Regulatory safety assessment
FDA · CJC forms and human exposure
The assessment distinguishes CJC-1295 forms, including the drug-affinity-complex construct. Human results for that long-acting material cannot establish the exposure, efficacy or safety of a product labeled only CJC or no DAC.
Read the original sourceEight-man crossover · acute GH release
Acute randomized crossover study
Tiulpakov AN et al. Clinical Endocrinology, 1995. PMID 7586605.
Eight healthy men received intravenous GHRH(1-29) amide, GHRP-2 and their combination in randomized order. The combination increased GH exposure, but did not significantly exceed the sum of the separate responses. No long-term body-composition or functional outcome was tested.
Read the original sourceFDA · ingredient safety concerns
Regulatory safety assessment
FDA · ingredient safety concerns
FDA identifies incomplete human safety data and peptide impurity or immune-reaction concerns for several ingredients used in these blends. Its CJC-1295 entry reports increased heart rate and a systemic vasodilatory reaction. For ipamorelin, serious events, including deaths, occurred in an intravenous study; this does not establish causation or the risk of other routes. BPC-157, injectable GHK-Cu and KPV have substantial route-specific safety gaps.
Read the original sourceExact combination · no controlled outcome study
Literature and registry record set
PubMed and public trial records.
The cited records contain no controlled outcome study of a chemically specified CJC-1295/ipamorelin fixed blend.
- The cited records contain no published or registered controlled study of a CJC-1295/ipamorelin fixed blend.
Why is cjc+ipa blend in A tier?
A reflects the receptor-pair logic behind the mixture and the component-level pharmacology of each ingredient. No controlled outcome trial has tested the finished blend, and only the identified DAC form has long-acting human exposure data.
how tiers are graded: methodology · every cited source · about reptides.
Research reference, not medical advice. Entries distinguish product labels, study doses and reported protocols. Check the linked source for the product, route and population.